Boston’s Intarcia Therapeutics, has a trusting investor syndicate backing its solo efforts to develop a late-stage GLP-1 treatment, and a peek at the company’s interim data on the once-a-year drug helps explain their faith.

…read more

Source: Intarcia’s once-a-year diabetes treatment shines in early PhIII results


0 No comments